Adverse events in IBD therapy: the 2018 update. (2nd December 2018)

• Record Type: Journal Article
• Authors: Quezada, Sandra M.; McLean, Leon P.; Cross, Raymond K.
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 12:Number 12(2018)
• Page Start: 1183
• Page End: 1191
• Publication Date: 2018-12-02
• Subjects: Inflammatory bowel disease -- Crohn's disease -- ulcerative colitis -- azathioprine -- mercaptopurine -- methotrexate -- anti-TNF -- anti-integrin -- anti-IL 12/IL 23; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2018.1545574
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Introduction : Crohn's disease and ulcerative colitis affect an increasing number of patients, and utilization of immune suppressant and biologic therapies is also increasing. These agents are linked to adverse events ranging from mild nuisance symptoms to potentially life-threatening complications including infections and malignancies. Areas covered : This review provides an updated discussion on adverse events associated with immunomodulator, anti-TNF-α, anti-integrin, and anti-IL 12/IL-23 antibody therapies. In addition, we review the risk profile of the currently widely available infliximab biosimilar medication. Expert commentary : Providers should engage in risk-benefit discussion with information specific to each medication discussed, and consider individualized risk factors when selecting therapeutic agents. Drug monitoring and shared decision-making results in more personalized medical management of inflammatory bowel disease.